Koshinski Asset Management Inc. Has $12.87 Million Position in Johnson & Johnson $JNJ

Koshinski Asset Management Inc. raised its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 83.1% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 84,230 shares of the company's stock after buying an additional 38,230 shares during the quarter. Johnson & Johnson comprises 1.0% of Koshinski Asset Management Inc.'s portfolio, making the stock its 19th biggest position. Koshinski Asset Management Inc.'s holdings in Johnson & Johnson were worth $12,866,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently modified their holdings of JNJ. Brighton Jones LLC grew its position in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock worth $7,502,000 after buying an additional 6,332 shares during the period. Wealth Group Ltd. acquired a new position in shares of Johnson & Johnson in the 1st quarter valued at approximately $218,000. GAMMA Investing LLC grew its position in shares of Johnson & Johnson by 48.0% in the 1st quarter. GAMMA Investing LLC now owns 43,508 shares of the company's stock valued at $7,215,000 after purchasing an additional 14,118 shares during the period. L.M. Kohn & Company grew its position in shares of Johnson & Johnson by 186.9% in the 1st quarter. L.M. Kohn & Company now owns 34,460 shares of the company's stock valued at $5,715,000 after purchasing an additional 22,449 shares during the period. Finally, Compass Ion Advisors LLC grew its position in shares of Johnson & Johnson by 6.0% in the 1st quarter. Compass Ion Advisors LLC now owns 14,556 shares of the company's stock valued at $2,414,000 after purchasing an additional 830 shares during the period. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the sale, the executive vice president owned 178,013 shares in the company, valued at approximately $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.16% of the company's stock.

Johnson & Johnson Trading Up 0.6%

Shares of Johnson & Johnson stock opened at $193.27 on Monday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $194.40. The stock has a market cap of $465.45 billion, a P/E ratio of 18.65, a P/E/G ratio of 2.27 and a beta of 0.40. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The business's 50 day moving average is $180.49 and its 200-day moving average is $164.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.08% and a net margin of 27.26%.The company had revenue of $24.02 billion for the quarter. Equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson's dividend payout ratio is 50.19%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on JNJ shares. UBS Group boosted their price objective on Johnson & Johnson from $190.00 to $214.00 and gave the company a "buy" rating in a research report on Tuesday, October 14th. Royal Bank Of Canada reiterated an "outperform" rating and issued a $209.00 price objective on shares of Johnson & Johnson in a research report on Friday, October 10th. The Goldman Sachs Group boosted their price objective on Johnson & Johnson from $186.00 to $212.00 and gave the company a "buy" rating in a research report on Thursday, October 9th. Morgan Stanley set a $190.00 target price on Johnson & Johnson in a research note on Wednesday. Finally, Stifel Nicolaus boosted their target price on Johnson & Johnson from $165.00 to $190.00 and gave the company a "hold" rating in a research note on Wednesday. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $199.88.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.